Molecules 2011, 16(4), 2982-2989; doi:10.3390/molecules16042982
Communication

Assessment of the In Vivo Genotoxicity of New Lead Compounds to Treat Sickle Cell Disease

1 Laboratório de Pesquisa e Desenvolvimento de Fármacos (Lapdesf), Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas, Univ Estadual Paulista (UNESP), Rodovia Araraquara Jaú Km. 01, 14801-902, Araraquara, SP, Brazil 2 Departamento de Ciências Biológicas, Faculdade de Ciências Farmacêuticas, Univ Estadual Paulista (UNESP), Rodovia Araraquara Jaú Km. 01, 14801-902, Araraquara, SP, Brazil 3 Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Faculdade de Farmácia, Univ Federal do Rio de Janeiro (UFRJ), Centro de Ciências da Saúde, Cidade Universitária, Ilha do Fundão, 21.944-190–Rio de Janeiro, RJ, Brazil
* Author to whom correspondence should be addressed.
Received: 8 February 2011; in revised form: 31 March 2011 / Accepted: 2 April 2011 / Published: 6 April 2011
(This article belongs to the collection Bioactive Compounds)
PDF Full-text Download PDF Full-Text [132 KB, uploaded 6 April 2011 11:19 CEST]
Abstract: The compounds 1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl nitrate (C1), (1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl nitrate (C2), 3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)benzyl nitrate (C3), 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-hydroxy-benzenesulfonamide (C4), 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)benzyl nitrate (C5), and 2-[4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)phenyl]ethyl nitrate (C6) were evaluated with a micronucleus test using mouse peripheral blood to identify new candidate drugs for the treatment of sickle cell disease (SCD) that are safer than hydroxyurea. The compounds induced an average frequency of micronucleated reticulocytes (MNRET) of less than six per 1,000 cells at 12.5, 25, 50, and 100 mg/kg, whereas hydroxyurea induced an average MNRET frequency of 7.8, 9.8, 15, and 33.7 per 1000 cells respectively, at the same concentrations. Compounds C1–C6 are new non-genotoxic in vivo candidate drugs for the treatment of SCD symptoms.
Keywords: genotoxicity assay; micronucleus; sickle cell; phthalimide derivatives

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Dos Santos, J.L.; Longhin Bosquesi, P.; Varanda, E.A.; Moreira Lima, L.; Chung, M.C. Assessment of the In Vivo Genotoxicity of New Lead Compounds to Treat Sickle Cell Disease. Molecules 2011, 16, 2982-2989.

AMA Style

Dos Santos JL, Longhin Bosquesi P, Varanda EA, Moreira Lima L, Chung MC. Assessment of the In Vivo Genotoxicity of New Lead Compounds to Treat Sickle Cell Disease. Molecules. 2011; 16(4):2982-2989.

Chicago/Turabian Style

Dos Santos, Jean Leandro; Longhin Bosquesi, Priscila; Varanda, Eliana Aparecida; Moreira Lima, Lídia; Chung, Man Chin. 2011. "Assessment of the In Vivo Genotoxicity of New Lead Compounds to Treat Sickle Cell Disease." Molecules 16, no. 4: 2982-2989.

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert